By: Andrea Stippler, Niels Eckstein, Elmar Kroth
Stippler A, Eckstein N, Kroth E. To switch or not to switch – German physicians´ views on proposed new OTC medicines. SelfCare 2019;10(1)11-23.
Rx-to-OTC switch


by Soller R W
Safe Use Conditions proposed by FDA may re-open door for switch in US: Has the OTC Drug Facts Label fallen victim to the Peter Principle? SelfCare 2012;3(2):19-20

by Schifkovitz D
Schifkovitz D. A prototype computer kiosk and algorithm to assist consumers with self-selection. SelfCare 2012;3(4):84-86

by Soller RW, Tong T, Koda Kimble MA, Juhl R, Lam YWF, Rice L
Soller RW, Tong T, Koda Kimble MA, Juhl R, Lam YWF, Rice L. Guiding principles for addressing Rx-to-OTC switch in the context of novel conditions of use for nonprescription medicines. SelfCare 2012;3(4):78-83

by Woodcock J
Woodcock J. Presentation to FDA hearing on Rx to OTC switch. SelfCare 2012;3(4):75-77

Notice of public hearing. SelfCare 2012;3(4):69-74

by Soller R W, Mann S
Thought leaders of self-care announcing a new program of leading public commentaries on self-care. SelfCare 2012;3(4):67-68

by Soller RW, Shaheen C
Soller RW, Shaheen C. The Switch Considerations List: ‘Considerations for Rx-to-OTC Switch’ Refined by a Critical Synthesis of FDA Comments on Expanded Access for Naloxone. SelfCare 2012;3(6):121-137
The Food and Drug Administration (FDA) recently held a meeting to explore new paradigms for drug availability under the regulatory rubric of novel conditions of nonprescription drug use. Subsequent to this meeting, FDA held a workshop on naloxone for prevention of death from opioid overdose. This represented the first publicly discussed switch candidate for novel conditions of nonprescription drug use.

by R William Soller
Soller RW. Regulatory Science Implications of Expanded Medication Access for Treatment of Overactive Bladder. SelfCare 2013;4(2):23-37

by R William Soller
Soller RW. Plan B in the Crucible of Science and Politics. SelfCare 2013;4(3):61-65